




Belgian Cancer Registry

CANCER FACT SHEET 2024

PROSTATE CANCER

ICD-10 C61



CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ($=200 \times 1.05$) and 255/100,000 over 5 years ($=200 \times (1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Histopathological Grade Group: is a grading system for prostate cancer, based on how similar the tumour is to the normal tissue (i.e., differentiation). Based on the Gleason Score, prostatic carcinomas can be divided into histopathological grade groups according to the International Society of Urological Pathology (ISUP) consensus on Gleason Grading.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2024, obtained from Statbel.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.



1. CANCER INCIDENCE	5
1.1. Prostate cancer incidence: by region	5
1.1.1. Prostate cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024	5
1.2. Prostate cancer incidence: by Histopathological Grade Group	6
1.2.1. Prostate cancer incidence by Histopathological Grade Group and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024	6
1.3. Prostate cancer incidence: by cancer dissemination	7
1.3.1. Prostate cancer incidence by cancer dissemination and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024	7
2. CANCER INCIDENCE TRENDS	8
2.1. Prostate cancer incidence trends: by region	8
2.1.1. Prostate cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024	8
2.2. Prostate cancer incidence trends: by Histopathological Grade Group	10
2.2.1. Prostate cancer incidence trends by Histopathological Grade Group: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards	10
2.3. Prostate cancer incidence trends: by cancer dissemination	12
2.3.1. Prostate cancer incidence trends by cancer dissemination: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards ...	12
2.4. Prostate cancer incidence trends: by age group	13
2.4.1. Prostate cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024	13
3. CANCER PREVALENCE	14
3.1. Prostate cancer prevalence: by region	14
3.1.1. Prostate cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024	14
4. CANCER SURVIVAL	15
4.1. Prostate cancer survival: by region	15
4.1.1. Prostate cancer survival by region and age group: number at risk and net survival probabilities, 2015-2024	15
4.2. Prostate cancer survival: by Histopathological Grade Group	17
4.2.1. Prostate cancer survival by Histopathological Grade Group: number at risk and net survival probabilities, 2015-2024	17
4.3. Prostate cancer survival: by cancer dissemination	18
4.3.1. Prostate cancer survival by cancer dissemination: number at risk and net survival probabilities, 2015-2024	18
5. CANCER SURVIVAL TRENDS	19
5.1. Prostate cancer survival trends: by Histopathological Grade Group	19

5.1.1. Prostate cancer survival trends by Histopathological Grade Group: number at risk and net survival probabilities, 2004-2024	19
5.2. Prostate cancer survival trends: by cancer dissemination	21
5.2.1. Prostate cancer survival trends by cancer dissemination: number at risk and net survival probabilities, 2004-2024	21
6. CANCER MORTALITY	22
6.1. Prostate cancer mortality: by region	22
6.1.1. Prostate cancer mortality* by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023	22
7. CANCER MORTALITY TRENDS	23
7.1. Prostate cancer mortality trends: by region	23
7.1.1. Prostate cancer mortality* trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023	23

1. CANCER INCIDENCE



1.1. Prostate cancer incidence: by region

1.1.1. Prostate cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024

Region	N [CR]																					ESR2013 (95%CI)
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	
Belgium	2	0	1	0	0	0	0	3	20	100	334	968	1,757	2,498	2,635	2,453	1,133	509	100	22	12,535	224.1
	[0.7]	[0.0]	[0.3]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[5.2]	[26.8]	[85.0]	[242.9]	[462.4]	[768.9]	[981.0]	[1,151.8]	[895.3]	[619.7]	[306.8]	[345.0]	[216.2]	(220.1; 228.0)
Brussels	0	0	0	0	0	0	0	0	3	6	22	66	123	147	148	135	84	38	5	6	783	205.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[6.6]	[13.6]	[53.3]	[182.2]	[416.3]	[675.8]	[871.4]	[1,048.9]	[1,021.0]	[750.2]	[222.7]	[1,065.7]	[127.9]	(190.7; 220.0)
Flanders	2	0	1	0	0	0	0	3	15	69	210	632	1,104	1,606	1,699	1,634	738	328	62	10	8,113	232.3
	[1.2]	[0.0]	[0.5]	[0.0]	[0.0]	[0.0]	[0.0]	[1.4]	[6.7]	[32.5]	[92.9]	[264.6]	[475.1]	[799.9]	[1,022.9]	[1,209.9]	[881.0]	[589.7]	[283.5]	[237.6]	[240.2]	(227.2; 237.4)
Wallonia	0	0	0	0	0	0	0	0	2	25	102	270	530	745	788	684	311	143	33	6	3,639	213.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.7]	[21.5]	[81.1]	[218.6]	[449.0]	[727.9]	[921.4]	[1,051.8]	[900.0]	[666.3]	[389.2]	[374.1]	[201.3]	(206.0; 220.0)

1.2. Prostate cancer incidence: by Histopathological Grade Group

1.2.1. Prostate cancer incidence by Histopathological Grade Group and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Histopathological Grade Group	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+	
I	441 [13.0]	1,801 [185.0]	832 [180.6]	3,074 [53.0]	54.4 (52.4; 56.3)
II	492 [14.5]	1,984 [203.8]	1,017 [220.8]	3,493 [60.3]	62.0 (59.9; 64.0)
III	248 [7.3]	1,439 [147.8]	806 [175.0]	2,493 [43.0]	44.4 (42.6; 46.1)
IV	107 [3.2]	743 [76.3]	608 [132.0]	1,458 [25.1]	26.3 (25.0; 27.7)
V	117 [3.5]	841 [86.4]	742 [161.1]	1,700 [29.3]	30.9 (29.4; 32.4)
X	20 [0.6]	82 [8.4]	212 [46.0]	317 [5.5]	6.2 (5.5; 6.9)

1.3. Prostate cancer incidence: by cancer dissemination

1.3.1. Prostate cancer incidence by cancer dissemination and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Cancer dissemination	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+	
No metastasis	1,279 [37.8]	6,031 [619.6]	3,412 [740.7]	10,722 [185.0]	191.0 (187.3; 194.6)
Regional lymph nodes only	68 [2.0]	412 [42.3]	200 [43.4]	682 [11.8]	12.1 (11.2; 13.0)
Distant metastasis	78 [2.3]	447 [45.9]	605 [131.3]	1,131 [19.5]	21.0 (19.8; 22.3)

2. CANCER INCIDENCE TRENDS



2.1. Prostate cancer incidence trends: by region

2.1.1. Prostate cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	N	9,730	9,739	9,286	9,000	8,899	8,734	8,765	9,130	8,347	7,949	7,996	8,435	9,134	9,618	9,873	10,269	9,753	11,800	12,706	12,437	12,535		
	CR	191.3	190.5	180.5	173.7	170.4	165.8	165.0	170.0	154.2	145.9	146.1	153.2	164.9	172.7	176.4	182.5	172.3	207.8	222.6	215.9	216.2		
	ESR2013	246.3	243.2	226.4	214.9	209.3	202.0	199.9	204.8	183.0	171.3	170.2	176.8	187.6	194.4	196.3	200.8	187.4	223.3	235.6	226.4	224.1	-0.2 (-0.5; 0.1)	2004-2024
																							-3.5 (-4.1; -2.8)	2004-2014
																							3.1 (2.4; 3.8)	2015-2024
Brussels	N	598	670	587	547	614	567	537	612	557	584	555	526	574	569	588	618	562	662	829	760	783		
	CR	124.5	138.5	119.9	110.1	121.5	109.8	101.9	112.8	100.7	104.0	97.9	91.8	99.0	97.7	100.2	104.3	94.0	110.5	138.1	124.9	127.9		
	ESR2013	187.3	211.7	183.9	171.8	188.1	173.5	163.4	183.4	165.2	172.3	161.2	153.3	165.9	164.6	168.5	172.6	155.3	179.9	220.8	199.8	205.4	0.3 (-0.2; 0.8)	2004-2024
																							-1.8 (-2.7; -0.9)	2004-2016
																							3.6 (2.1; 5.0)	2017-2024
Flanders	N	5,932	6,142	5,959	5,986	5,873	5,765	5,716	5,940	5,492	5,028	5,126	5,449	5,932	6,260	6,499	6,706	6,614	7,806	8,256	8,234	8,113		
	CR	200.0	206.1	198.8	198.4	193.2	188.1	185.3	190.8	175.2	159.5	161.9	171.2	185.3	194.3	200.5	205.7	201.6	237.0	248.9	245.6	240.2		
	ESR2013	247.0	251.0	236.6	232.3	224.4	215.8	210.3	215.1	194.0	174.6	175.2	183.4	195.8	203.0	207.0	210.1	203.4	236.3	245.1	239.8	232.3	-0.2 (-0.5; 0.1)	2004-2024
																							-3.4 (-4.1; -2.8)	2004-2014

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
																						3.2 (2.5; 3.8)	2015-2024
Wallonia N	3,200	2,927	2,740	2,467	2,412	2,402	2,512	2,578	2,298	2,337	2,315	2,460	2,628	2,789	2,786	2,945	2,577	3,332	3,621	3,443	3,639		
CR	195.1	177.6	165.4	147.9	143.7	142.3	147.8	150.4	133.2	134.7	132.9	140.6	149.6	158.1	157.4	165.8	144.6	186.7	202.1	191.2	201.3		
ESR2013	260.5	235.2	216.9	190.8	184.0	181.1	187.8	188.7	164.8	164.3	162.6	169.6	176.6	184.2	181.7	188.9	162.8	206.8	220.4	205.7	213.0	-0.6 (-1.0; -0.1)	2004-2024
																						-4.4 (-5.5; -3.2)	2004-2013
																						2.7 (1.7; 3.7)	2014-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Prostate cancer incidence trends: by Histopathological Grade Group

2.2.1. Prostate cancer incidence trends by Histopathological Grade Group: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

Histopathological Grade Group		2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
I	N	2,098	2,762	3,325	3,122	3,074		
	CR	37.1	48.7	58.2	54.2	53.0		
	ESR2013	39.9	51.6	60.7	56.0	54.4	-2.5 (-3.7; -1.2)	2004-2024
							1.9 (-4.2; 8.3)	2004-2009
II	N	2,657	3,262	3,355	3,344	3,493		
	CR	46.9	57.5	58.8	58.0	60.3		
	ESR2013	50.1	60.9	61.4	60.0	62.0	-12.3 (-17.5; -6.8)	2010-2013
							-0.7 (-2.9; 1.6)	2014-2024
III	N	1,897	2,259	2,357	2,335	2,493		
	CR	33.5	39.8	41.3	40.5	43.0		
	ESR2013	36.5	42.5	43.7	42.5	44.4	4.4 (3.6; 5.3)	2004-2024
							26.1 (15.7; 37.4)	2004-2006
IV	N	1,399	1,552	1,556	1,562	1,458		
	CR	24.7	27.3	27.3	27.1	25.1		
	ESR2013	27.2	29.9	29.3	28.8	26.3	2.2 (1.5; 3.0)	2007-2024
	N							
	CR							
	ESR2013						6.2 (5.1; 7.5)	2004-2024
							6.9 (5.9; 7.9)	2004-2022
	N							
	CR							
	ESR2013						0.4 (-10.8; 13.1)	2023-2024
	N							
	CR							
	ESR2013						2.5 (1.7; 3.3)	2004-2024
							2.4 (-0.5; 5.4)	2004-2010
	N							
	CR							
	ESR2013						2.5 (1.4; 3.7)	2011-2024

Histopathological Grade Group		2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
V	N	1,406	1,613	1,687	1,749	1,700		
	CR	24.8	28.4	29.6	30.4	29.3		
	ESR2013	27.6	31.2	31.9	32.6	30.9	3.9 (2.9; 4.8)	2004-2024
							4.9 (3.7; 6.1)	2004-2019
							0.8 (-3.2; 5.1)	2020-2024
X	N	296	352	426	325	317		
	CR	5.2	6.2	7.5	5.6	5.5		
	ESR2013	6.1	7.3	8.6	6.4	6.2	-11.0 (-12.3; -9.6)	2004-2024
							-23.1 (-25.9; -20.1)	2004-2013
							0.3 (-2.7; 3.3)	2014-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Prostate cancer incidence trends: by cancer dissemination

2.3.1. Prostate cancer incidence trends by cancer dissemination: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

Cancer dissemination		2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
No metastasis	N	8,189	10,080	10,867	10,594	10,722		
	CR	144.7	177.6	190.4	183.9	185.0		
	ESR2013	156.7	190.1	200.7	192.0	191.0	-0.9 (-1.3; -0.6)	2004-2024
							-4.3 (-5.0; -3.6)	2004-2014
							2.6 (1.8; 3.3)	2015-2024
Regional lymph nodes only	N	631	685	731	717	682		
	CR	11.1	12.1	12.8	12.4	11.8		
	ESR2013	12.0	12.8	13.4	12.9	12.1	7.0 (6.5; 7.6)	2004-2024
							9.3 (8.5; 10.1)	2004-2018
							1.9 (-0.1; 3.9)	2019-2024
Distant metastasis	N	933	1,035	1,108	1,126	1,131		
	CR	16.5	18.2	19.4	19.5	19.5		
	ESR2013	18.7	20.4	21.5	21.4	21.0	5.8 (5.1; 6.6)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.4. Prostate cancer incidence trends: by age group

2.4.1. Prostate cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, %	(95%CI)	Period
15-59	N	1,467	1,586	1,503	1,475	1,560	1,377	1,355	1,437	1,315	1,234	1,139	1,174	1,261	1,299	1,288	1,286	1,160	1,442	1,524	1,491	1,425			
	CR	45.9	49.5	46.6	45.6	48.0	42.1	41.3	43.5	39.6	37.1	34.3	35.3	37.8	39.0	38.6	38.5	34.7	43.2	45.5	44.3	42.1			
	ESR2013	50.6	53.3	49.4	48.3	50.6	44.3	43.0	44.9	40.5	37.4	34.1	34.7	36.9	37.6	37.1	36.7	33.1	40.9	43.4	42.6	41.1	-1.3	(-1.8; -0.9)	2004-2024
																							-3.9	(-4.8; -3.1)	2004-2015
																							2.0	(0.8; 3.1)	2016-2024
60-74	N	5,260	5,141	5,078	4,815	4,655	4,732	4,606	4,881	4,466	4,287	4,255	4,511	4,976	5,347	5,533	5,672	5,477	6,563	7,114	6,961	6,890			
	CR	773.0	750.5	739.2	687.9	653.2	650.7	621.4	645.7	580.5	547.3	534.0	555.1	597.6	624.1	629.3	631.4	597.4	702.3	752.4	725.8	707.8			
	ESR2013	768.1	746.4	738.9	694.9	667.5	665.7	637.3	665.1	596.1	561.8	550.1	572.4	614.3	640.3	641.4	642.3	608.4	713.1	765.2	739.6	721.7	-0.1	(-0.4; 0.2)	2004-2024
																							-3.1	(-3.8; -2.5)	2004-2014
																							2.9	(2.2; 3.6)	2015-2024
75+	N	3,003	3,012	2,705	2,710	2,684	2,625	2,804	2,812	2,566	2,428	2,601	2,750	2,897	2,972	3,052	3,311	3,116	3,795	4,068	3,984	4,217			
	CR	1,024.4	995.1	861.3	831.9	797.0	759.6	792.0	778.5	695.2	645.6	678.3	702.5	733.8	752.8	768.3	819.4	753.6	912.1	943.5	894.7	915.5			
	ESR2013	999.5	987.0	840.1	799.9	772.6	736.8	772.5	764.5	677.3	630.5	660.0	689.7	718.5	741.5	764.3	815.2	751.9	907.4	933.0	881.7	898.8	-0.2	(-0.5; 0.2)	2004-2024
																							-4.4	(-5.3; -3.5)	2004-2013
																							3.4	(2.7; 4.2)	2014-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3. CANCER PREVALENCE



3.1. Prostate cancer prevalence: by region

3.1.1. Prostate cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024

Region		1-year	5-year	10-year	15-year	20-year
Belgium	N	12,260	53,656	86,596	107,658	123,542
	CR	210.3	920.3	1,485.3	1,846.6	2,119.1
	ESR2013	215.5	949.5	1,544.3	1,931.8	2,230.6
Brussels	N	752	3,161	4,923	6,172	7,028
	CR	122.2	513.7	800.0	1,003.0	1,142.1
	ESR2013	194.8	833.3	1,329.1	1,689.8	1,944.5
Flanders	N	7,961	35,696	57,802	71,996	82,826
	CR	234.2	1,049.9	1,700.1	2,117.6	2,436.2
	ESR2013	224.1	1,006.5	1,634.4	2,041.6	2,355.6
Wallonia	N	3,547	14,799	23,871	29,490	33,688
	CR	195.4	815.4	1,315.3	1,624.9	1,856.2
	ESR2013	204.1	860.7	1,409.7	1,760.5	2,035.0

4. CANCER SURVIVAL



4.1. Prostate cancer survival: by region

4.1.1. Prostate cancer survival by region and age group: number at risk and net survival probabilities, 2015-2024

Net Survival Probability, 2015-2024						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Belgium	All ages 15+	106,311	99.5% (99.4%; 99.6%)	98.4% (98.2%; 98.6%)	97.9% (97.5%; 98.3%)	97.0% (95.7%; 98.2%)
	15-59	13,317	99.9% (99.7%; 100.0%)	98.8% (98.5%; 99.2%)	97.8% (97.3%; 98.2%)	95.8% (94.8%; 96.7%)
	60-74	58,906	99.9% (99.8%; 100.0%)	99.3% (99.0%; 99.5%)	98.8% (98.5%; 99.1%)	98.1% (97.2%; 99.0%)
	75+	34,088	98.7% (98.4%; 99.0%)	96.7% (96.1%; 97.4%)	96.3% (95.3%; 97.3%)	95.4% (91.8%; 99.3%)
Brussels	All ages 15+	6,400	99.5% (99.0%; 100.1%)	98.3% (97.2%; 99.4%)	96.7% (95.0%; 98.5%)	96.5% (91.6%; 101.8%)
	15-59	875	99.5% (98.8%; 100.2%)	97.7% (96.3%; 99.2%)	96.4% (94.4%; 98.4%)	93.8% (89.7%; 98.1%)
	60-74	3,450	99.9% (99.4%; 100.4%)	99.6% (98.5%; 100.6%)	98.6% (97.0%; 100.2%)	95.9% (91.7%; 100.3%)
	75+	2,075	98.8% (97.4%; 100.2%)	96.4% (93.6%; 99.2%)	93.8% (89.3%; 98.5%)	98.5% (85.3%; 113.8%)
Flanders	All ages 15+	69,766	99.6% (99.4%; 99.7%)	98.6% (98.4%; 98.9%)	98.3% (97.8%; 98.7%)	95.9% (94.4%; 97.4%)
	15-59	8,855	99.9% (99.7%; 100.0%)	99.0% (98.7%; 99.4%)	98.0% (97.5%; 98.5%)	95.7% (94.6%; 96.9%)
	60-74	38,062	100.0% (99.9%; 100.1%)	99.5% (99.3%; 99.8%)	99.1% (98.7%; 99.5%)	98.7% (97.7%; 99.8%)
	75+	22,849	98.7% (98.4%; 99.1%)	97.0% (96.3%; 97.7%)	97.1% (95.9%; 98.2%)	91.1% (86.8%; 95.6%)
Wallonia	All ages 15+	30,145	99.4% (99.1%; 99.6%)	97.9% (97.4%; 98.4%)	97.2% (96.4%; 97.9%)	99.3% (96.7%; 101.8%)
	15-59	3,587	99.9% (99.6%; 100.2%)	98.7% (98.1%; 99.4%)	97.6% (96.7%; 98.6%)	96.2% (94.2%; 98.3%)
	60-74	17,394	99.7% (99.5%; 100.0%)	98.6% (98.2%; 99.1%)	98.1% (97.4%; 98.8%)	97.0% (95.2%; 98.8%)

Net Survival Probability, 2015-2024						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	75+	9,164	98.5% (97.9%; 99.2%)	96.1% (94.8%; 97.4%)	95.1% (93.1%; 97.2%)	104.5% (96.9%; 112.7%)

4.2. Prostate cancer survival: by Histopathological Grade Group

4.2.1. Prostate cancer survival by Histopathological Grade Group: number at risk and net survival probabilities, 2015-2024

Histopathological Grade Group	Net Survival Probability, 2015-2024						
	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	106,311	99.5% (99.4%; 99.6%)	99.0% (98.8%; 99.2%)	98.4% (98.2%; 98.6%)	98.0% (97.7%; 98.3%)	97.9% (97.5%; 98.3%)	97.0% (95.7%; 98.2%)
I	26,399	100.2% (100.0%; 100.4%)	100.7% (100.4%; 101.0%)	101.3% (100.9%; 101.7%)	102.3% (101.8%; 102.8%)	103.0% (102.4%; 103.7%)	109.1% (106.8%; 111.5%)
II	29,113	100.8% (100.6%; 101.0%)	101.8% (101.6%; 102.1%)	102.8% (102.5%; 103.1%)	103.7% (103.3%; 104.2%)	104.7% (104.1%; 105.3%)	108.3% (106.2%; 110.4%)
III	19,157	101.0% (100.8%; 101.2%)	101.9% (101.5%; 102.2%)	102.5% (102.0%; 103.0%)	103.1% (102.5%; 103.7%)	103.7% (102.9%; 104.5%)	102.5% (99.6%; 105.6%)
IV	13,472	99.5% (99.1%; 99.9%)	98.8% (98.3%; 99.4%)	98.1% (97.4%; 98.8%)	97.5% (96.5%; 98.4%)	96.7% (95.6%; 97.9%)	88.2% (84.0%; 92.5%)
V	14,972	97.1% (96.7%; 97.5%)	92.2% (91.5%; 92.9%)	86.7% (85.8%; 87.6%)	81.7% (80.6%; 82.8%)	78.4% (77.2%; 79.7%)	64.0% (60.5%; 67.6%)
X	3,203	84.8% (83.2%; 86.4%)	73.9% (71.8%; 76.0%)	66.4% (64.0%; 69.0%)	60.7% (57.9%; 63.7%)	55.9% (52.7%; 59.3%)	42.2% (34.0%; 52.4%)

4.3. Prostate cancer survival: by cancer dissemination

4.3.1. Prostate cancer survival by cancer dissemination: number at risk and net survival probabilities, 2015-2024

Cancer dissemination	Net Survival Probability, 2015-2024						
	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	106,311	99.5% (99.4%; 99.6%)	99.0% (98.8%; 99.2%)	98.4% (98.2%; 98.6%)	98.0% (97.7%; 98.3%)	97.9% (97.5%; 98.3%)	97.0% (95.7%; 98.2%)
No metastasis	91,087	100.6% (100.4%; 100.7%)	101.2% (101.1%; 101.4%)	101.9% (101.6%; 102.1%)	102.4% (102.1%; 102.7%)	102.9% (102.5%; 103.2%)	104.5% (103.1%; 105.8%)
Regional lymph nodes only	6,113	100.3% (99.9%; 100.8%)	99.9% (99.2%; 100.6%)	97.9% (96.9%; 98.8%)	96.7% (95.5%; 97.9%)	95.5% (94.0%; 96.9%)	79.9% (74.1%; 86.1%)
Distant metastasis	9,115	88.6% (87.8%; 89.4%)	75.5% (74.4%; 76.7%)	63.9% (62.6%; 65.3%)	55.0% (53.5%; 56.5%)	48.8% (47.2%; 50.5%)	28.3% (25.0%; 32.1%)

5. CANCER SURVIVAL TRENDS



5.1. Prostate cancer survival trends: by Histopathological Grade Group

5.1.1. Prostate cancer survival trends by Histopathological Grade Group: number at risk and net survival probabilities, 2004-2024

Period	Histopathological Grade Group	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2024	Total	193,845	99.1% (99.0%; 99.2%)	97.4% (97.3%; 97.6%)	96.4% (96.1%; 96.7%)
2004-2009	I	19,278	99.9% (99.7%; 100.2%)	100.7% (100.2%; 101.2%)	101.5% (100.8%; 102.3%)
	II	8,835	99.8% (99.4%; 100.3%)	99.8% (99.1%; 100.6%)	99.9% (98.8%; 101.0%)
	III	3,688	99.3% (98.6%; 100.0%)	98.3% (97.0%; 99.6%)	96.2% (94.3%; 98.0%)
	IV	4,180	97.4% (96.6%; 98.2%)	90.6% (89.0%; 92.1%)	85.6% (83.5%; 87.6%)
	V	3,712	94.0% (92.9%; 95.0%)	78.7% (76.8%; 80.6%)	69.7% (67.4%; 72.0%)
	X	5,767	95.1% (94.3%; 95.9%)	90.2% (88.9%; 91.5%)	87.4% (85.6%; 89.1%)
2010-2014	I	15,634	99.7% (99.4%; 100.0%)	99.9% (99.4%; 100.5%)	100.9% (100.1%; 101.7%)
	II	10,198	100.5% (100.1%; 100.8%)	101.4% (100.8%; 102.0%)	101.9% (101.0%; 102.9%)
	III	4,888	100.5% (100.0%; 101.0%)	100.1% (99.0%; 101.1%)	97.7% (96.1%; 99.3%)
	IV	4,566	98.4% (97.6%; 99.1%)	93.1% (91.8%; 94.5%)	88.5% (86.6%; 90.4%)
	V	4,562	94.2% (93.3%; 95.1%)	79.4% (77.8%; 81.1%)	68.6% (66.5%; 70.7%)
	X	2,238	89.1% (87.5%; 90.7%)	80.8% (78.4%; 83.3%)	77.8% (74.8%; 81.0%)
2015-2019	I	12,052	99.9% (99.5%; 100.2%)	100.4% (99.8%; 101.1%)	101.7% (100.9%; 102.6%)
	II	13,033	100.7% (100.4%; 101.0%)	102.8% (102.3%; 103.3%)	104.5% (103.8%; 105.3%)

Period	Histopathological Grade Group	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	III	7,833	100.8% (100.4%; 101.2%)	101.9% (101.1%; 102.6%)	102.6% (101.5%; 103.7%)
	IV	5,965	99.6% (99.0%; 100.1%)	97.0% (95.8%; 98.1%)	95.3% (93.7%; 96.9%)
	V	6,835	96.8% (96.1%; 97.5%)	84.9% (83.6%; 86.2%)	75.7% (74.0%; 77.4%)
	X	1,500	85.0% (82.8%; 87.4%)	65.5% (62.2%; 69.1%)	55.6% (51.5%; 60.1%)
2020-2024	I	14,347	100.5% (100.2%; 100.7%)	102.1% (101.6%; 102.6%)	104.7% (103.7%; 105.6%)
	II	16,080	100.9% (100.6%; 101.1%)	102.7% (102.3%; 103.2%)	105.0% (104.1%; 105.8%)
	III	11,324	101.1% (100.8%; 101.4%)	103.0% (102.4%; 103.6%)	105.0% (103.8%; 106.1%)
	IV	7,507	99.5% (99.0%; 100.0%)	99.1% (98.2%; 100.1%)	98.2% (96.5%; 100.0%)
	V	8,137	97.4% (96.8%; 98.0%)	88.4% (87.2%; 89.6%)	82.2% (80.3%; 84.2%)
	X	1,703	84.5% (82.3%; 86.7%)	67.7% (64.2%; 71.3%)	56.1% (50.9%; 61.8%)

5.2. Prostate cancer survival trends: by cancer dissemination

5.2.1. Prostate cancer survival trends by cancer dissemination: number at risk and net survival probabilities, 2004-2024

Period	Cancer dissemination	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2024	Total	203,481	99.1% (99.0%; 99.2%)	97.4% (97.2%; 97.6%)	96.3% (96.0%; 96.6%)
2004-2009	No metastasis	51,996	99.0% (98.8%; 99.2%)	98.1% (97.8%; 98.5%)	97.4% (96.9%; 97.9%)
	Regional lymph nodes only	1,098	99.2% (98.0%; 100.4%)	90.5% (88.0%; 93.1%)	82.6% (79.4%; 86.0%)
	Distant metastasis	2,002	84.2% (82.3%; 86.1%)	51.3% (48.7%; 54.1%)	36.3% (33.6%; 39.2%)
2010-2014	No metastasis	38,283	99.6% (99.4%; 99.8%)	99.0% (98.6%; 99.4%)	98.5% (97.9%; 99.0%)
	Regional lymph nodes only	1,546	99.4% (98.4%; 100.3%)	92.9% (90.9%; 95.0%)	86.0% (83.3%; 88.9%)
	Distant metastasis	2,257	82.8% (81.0%; 84.6%)	53.2% (50.8%; 55.8%)	36.5% (34.0%; 39.3%)
2015-2019	No metastasis	40,753	100.3% (100.2%; 100.5%)	101.1% (100.8%; 101.5%)	101.7% (101.1%; 102.2%)
	Regional lymph nodes only	2,672	100.0% (99.3%; 100.7%)	96.0% (94.5%; 97.4%)	93.8% (91.8%; 95.8%)
	Distant metastasis	3,791	87.5% (86.2%; 88.8%)	60.4% (58.4%; 62.4%)	44.4% (42.3%; 46.6%)
2020-2024	No metastasis	50,334	100.7% (100.6%; 100.9%)	102.6% (102.3%; 102.9%)	104.5% (103.9%; 105.0%)
	Regional lymph nodes only	3,441	100.6% (100.0%; 101.1%)	99.5% (98.2%; 100.8%)	97.2% (94.9%; 99.5%)
	Distant metastasis	5,324	89.3% (88.3%; 90.4%)	66.9% (65.1%; 68.7%)	53.5% (50.9%; 56.1%)

6. CANCER MORTALITY



6.1. Prostate cancer mortality: by region

6.1.1. Prostate cancer mortality* by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023

Region	N [CR]																				All ages	ESR2013 (95%CI)
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		
Belgium	0	0	0	0	0	0	0	0	0	4	5	18	56	88	144	259	286	332	225	68	1,485	30.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.1]	[1.3]	[4.5]	[14.9]	[27.7]	[54.1]	[127.4]	[229.0]	[416.4]	[718.1]	[1,122.1]	[25.8]	(29.1; 32.2)
Brussels	0	0	0	0	0	0	0	0	0	0	0	0	5	8	14	13	26	25	13	5	109	33.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[17.3]	[37.5]	[83.2]	[103.0]	[323.2]	[499.7]	[564.5]	[932.8]	[17.9]	(27.0; 39.6)
Flanders	0	0	0	0	0	0	0	0	0	3	2	12	35	49	88	171	173	217	140	41	931	29.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.4]	[0.9]	[5.0]	[15.3]	[25.0]	[53.6]	[131.2]	[209.9]	[403.4]	[673.0]	[1,032.7]	[27.8]	(27.5; 31.4)
Wallonia	0	0	0	0	0	0	0	0	0	1	3	6	16	31	42	75	87	90	72	22	445	33.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[2.4]	[4.8]	[13.7]	[30.7]	[49.2]	[124.4]	[252.9]	[430.1]	[875.3]	[1,415.7]	[24.7]	(29.9; 36.3)

7. CANCER MORTALITY TRENDS



7.1. Prostate cancer mortality trends: by region

7.1.1. Prostate cancer mortality* trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	N	1,369	1,515	1,416	1,371	1,422	1,402	1,514	1,508	1,394	1,455	1,430	1,532	1,523	1,572	1,602	1,576	1,581	1,495	1,542	1,485		
	CR	26.9	29.6	27.5	26.5	27.2	26.6	28.5	28.1	25.7	26.7	26.1	27.8	27.5	28.2	28.6	28.0	27.9	26.3	27.0	25.8		
	ESR2013	47.9	51.0	46.1	43.8	43.0	40.9	43.6	41.6	37.4	37.9	36.3	38.4	36.8	36.7	36.3	35.1	34.3	32.3	32.9	30.6	-2.2 (-2.5; -1.9)	2004-2023
Brussels	N	111	117	131	102	121	103	126	125	110	104	124	113	127	123	121	126	121	89	97	109		
	CR	23.1	24.2	26.8	20.5	23.9	20.0	23.9	23.0	19.9	18.5	21.9	19.7	21.9	21.1	20.6	21.3	20.2	14.9	16.2	17.9		
	ESR2013	42.7	42.5	47.7	37.5	43.1	36.8	41.5	42.0	38.5	33.9	41.1	35.6	41.8	38.5	38.3	39.6	37.5	28.0	30.1	33.3	-1.5 (-2.2; -0.7)	2004-2023
Flanders	N	805	901	857	868	829	857	917	927	863	914	878	948	925	1,000	1,028	966	1,009	961	977	931		
	CR	27.1	30.2	28.6	28.8	27.3	28.0	29.7	29.8	27.5	29.0	27.7	29.8	28.9	31.0	31.7	29.6	30.8	29.2	29.5	27.8		
	ESR2013	46.5	51.1	45.8	45.0	41.6	40.9	43.3	41.7	36.5	38.3	35.1	37.4	34.7	36.5	36.3	33.5	34.0	31.9	32.0	29.4	-2.3 (-2.7; -2.0)	2004-2023
Wallonia	N	453	497	428	401	472	442	471	456	421	437	428	471	471	449	453	484	451	445	468	445		
	CR	27.6	30.2	25.8	24.0	28.1	26.2	27.7	26.6	24.4	25.2	24.6	26.9	26.8	25.4	25.6	27.3	25.3	24.9	26.1	24.7		
	ESR2013	52.2	53.6	46.6	43.6	45.6	42.2	45.4	41.5	38.9	38.0	37.5	41.8	39.5	37.0	35.6	37.5	33.9	34.0	35.8	33.1	-2.1 (-2.6; -1.7)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2023.

Recommended reference: Cancer Fact Sheets 2024, Belgian Cancer Registry (BCR), 2026